

A Systematic Review of Oral Myofunctional Therapy for Future Treatment in Pediatric Obstructive Sleep Apnea (OSA)

Harun Achmad¹, Huldani², Nur Hildah Inayah³, Yunita Feby Ramadhan⁴

¹Lecture of Pediatric Dentistry, Department of Pediatric Dentistry Faculty of Dentistry, Hasanuddin University, Indonesia

²Department of Physiology, Faculty of Medicine, Lambung Mangkurat University, Banjarmasin, South Kalimantan, Indonesia

³Clinical Dental Student of Faculty of Dentistry, Hasanuddin University, Indonesia

⁴Dentist Faculty of Dentistry, Hasanuddin University, Makassar, Indonesia

Corresponding Author: harunachmader@gmail.com

Article History:

Submitted: 05.04.2020

Revised: 11.05.2020

Accepted: 23.06.2020

ABSTRACT

Obstructive sleep apnea (OSA) is a sleep-related respiratory disorder with a reduction or obstruction of total air flow despite continuous efforts with patients to breathe. The prevalence of OSA is around 2-4% in men and 1-2% in women. The American Academy of Pediatric Dentistry (AAPD) recognizes that obstructive sleep apnea (OSA) occurs in a pediatric population. Oral myofunctional therapy has emerged as an alternative treatment that allows for obstructive sleep apnea (OSA). The aim of this study is to systematically review the literature on oral myofunctional therapy for future care in children with obstructive sleep apnea (OSA). Data source of Web of Science, Scopus, and The Cochrane Library. Studies published from 2011 to 2020 that evaluate treatments with isolated oral myofunctional therapy in subjects with OSA. Sixty articles were assessed, including 60 articles from an electronic database, 50 records were filtered, 30

records were issued, 22 full-text articles were assessed for eligibility and 10 full-text articles were included. All of these articles say that myofunctional therapy has the potential to be an option for OSA treatment. Therefore a systematic literature review shows that oral myofunctional therapy for future treatment of obstructive sleep apnea in children (OSA).

Keywords: Obstructive Sleep Apnea; Myofunctional Therapy; Pediatric

Correspondence:

Harun Achmad

Lecturer of Pediatric Dentistry, Department of Pediatric Dentistry, Faculty of Dentistry, Hasanuddin University, Indonesia

E-mail: harunachmader@gmail.com

DOI: [10.31838/srp.2020.6.80](https://doi.org/10.31838/srp.2020.6.80)

©Advanced Scientific Research. All rights reserved

INTRODUCTION

Obstructive sleep apnea (OSA) is a respiratory disorder associated with sleep with obstruction of complete airflow to breathe. Usually occurs during sleep, the couch that causes blockage of the upper airway.¹ Consequently, there are several parts and total breathing pause which lasts at least 10 seconds during sleep.² Then, blood oxygen saturation, with oxygen levels dropping, suddenly and drops 50% or more in severe cases. The brain shows a compilation response of little oxygen and reminds the body that causes a brief arousal from sleep. This restores normal breathing patterns.¹ This pattern can occur several times in one night. This results in fragmentation in the quality of sleep and produces excessive daytime sleepiness.^{1,2}

Sleep-related disorders breathing encompass a broad spectrum of conditions, including obstructive sleep apnea (OSA), where recurrent partial or complete obstruction of the upper airway occurs. The prevalence of OSA is approximately 2–4% in men and 1–2% in women.³⁻⁷ It has been established that OSA is an independent risk factor for cerebrovascular and cardiovascular disease and can consequently lead to significant morbidity and mortality. Alongside the health-related impacts, OSA can also confer a considerable social and economic burden for those affected, and it has been suggested that the daytime sleepiness and resultant impaired cognitive function may contribute to job-related and motor vehicle accidents. Sleep-related respiratory disorders cover a wide spectrum of conditions, including obstructive sleep apnea (OSA), where partial or complete obstruction of the upper airway occurs. The prevalence of OSA is around 2-4% in men and 1-2% in women.³⁻⁷ It has been established that OSA is an independent risk factor for cerebrovascular and cardiovascular disease and consequently can cause

significant morbidity and mortality. In addition to health-related impacts, OSA can also impose significant social and economic burdens on those affected, and it has been suggested that daytime sleepiness and the resulting cognitive function can contribute to work-related accidents and motor vehicles. Separately, moderate to severe OSA has been reported to independently increase the risk of death of all causes. The burden of disease associated with OSA only tends to increase because worldwide obesity rates in the population increase.¹

The American Academy of Pediatric Dentistry (AAPD) recognizes that obstructive sleep apnea (OSA) occurs in a pediatric population. Undiagnosed and / or untreated OSA is associated with learning problems, cardiovascular complications, growth disorders (including failure to develop), and / or behavioral problems.⁸ To reduce these complications, AAPD encourages health professionals to routinely screen their patients for increased risk for OSA and to facilitate medical referral when indicated.

The pathophysiology of pediatric OSA is often multifactorial, with significant contributions from adenotonsillar hypertrophy, obesity, and genetics. Polysomnography is currently the most accepted diagnostic modality for OSA, but limited availability and high cost limits are routine.⁹ At present, there is no consensus among anesthesiologists regarding the best and safest anesthetic techniques for children with significant OSA; there is also a lack of agreement between anesthesiologists, surgeons and institutions on specific criteria for identifying children with OSA who will benefit from hospital admission and aggressive postoperative monitoring after surgery. The purpose of this review is for an overview of oral myofunctional therapies for future treatment in children with obstructive sleep apnea¹⁰

Diagnosis of OSA in children can be a challenge due to various symptoms that arise. The evaluation of children with suspected sleep disorders begins and, for the most part, ends with a thorough history.¹¹ OSA clinical presentations include behavioral and neurocognitive disorders, enuresis, cardiovascular sequelae, poor school performance, and headaches, , including systemic and pulmonary hypertension. It is important to note that parental reports alone do not distinguish OSA from simple primary snoring.¹² The accuracy of clinical evaluation of pediatric OSA in predicting poor sleep studies is poor, ranging from 30% to 85%.¹³

Further diagnostic evaluation of a child with a clinical history suggestive of OSA includes polysomnographic performance, which is considered a 'gold standard' for diagnosis and quantitative description of OSA.¹⁴ Children with snoring primary do not have other night and daytime symptoms and have normal sleep polysomnographic studies. Polysomnography continuously monitors physiological variables during different sleep phases and can distinguish primary snoring from OSA and

also provides a more complete description of obstructive events that occur during sleep.¹⁵ Central sleep apnea is characterized by polysomnography in the absence of airflow and respiratory effort. Some patients, especially those with neuromuscular conditions, can display a mixture of central and OSA¹⁶

Daytime polysomnography has been used to evaluate children with suspected Sleep Disorders, although normal nap studies are not enough to exclude the diagnosis of OSA in patients with manifestations clinical that suggest OSA.¹⁷ While the validity of portable monitoring modalities in the diagnosis of OSA in children is still unknown, there is increasing interest in their use in polysomnographic sites to increase access and reduce costs. One example of a portable monitoring modality is nocturnal oximetry, which assesses the severity of OSA by calculating the amount and severity of oxyhemoglobin desaturation during sleep. Isolated heavy desaturation (80%) or desaturation group (more than three episodes, 90%) are considered abnormal. The positive predictive value for oximetry is 97%.¹⁸

Table 1: McGill Oximetry Assessment System. The severity of OSA is determined by the presence of SpO₂ and the number of episodes during nocturnal oximetry. OSA, obstructive sleep apnea²

Oximetry Score	OSA Classification	Number of events of SpO ₂ <90%	Number of events of SpO ₂ <85%	Number of events of SpO ₂ <80%
1	Normal/Inconclusive for OSA	<3	None	None
2	Mild	≥3	≤3	None
3	Moderate	≥3	>3	≤3
4	Severe	≥3	>3	>3

Table 2: The severity of OSA by polysomnography (PSG) in children and adults as defined by the American Society of Anesthesiologists Task Force on Perioperative Management of Patients with Obstructive Sleep Apnea. OSA, obstructive sleep apnea; AHI, apnea / hypopnea index.²

OSA severity	AHI Children	AHI Adults
None	0	0-5
Mild	1-5	6-20
Moderate	6-10	21-40
Severe	>10	>40

Risk factors for the development of OSA in children include a family history of snoring or OSA, physical abnormalities, cerebral palsy, muscular dystrophy,¹⁹ Down syndrome, sickle cell disease, oral breathing, and any conditions that can cause narrowing in OSA. upper airway. An important common risk factor for OSA is obesity.²⁰ According to Tauman and Gozal, the recent increase in obesity has led to an increase in OSA prevalence among children, because this condition has been shown to be positively correlated with body mass index.²¹

Symptoms of Pediatric OSA include loud snoring 3 or more nights per week, episodes of respiratory arrest witnessed by others,²² sudden wakes accompanied by shortness of breath, mouth breathing including symptoms of dry mouth or sore throat, difficulty sleeping with several sleepless nights. day,²³ anxiety, sweating, waking up in the morning feeling not refreshed, and finally, frequent headaches in the morning.²⁴ Daytime consequences of Sleep Disorder Breathing can

affect the nervous system, cardiovascular system and/or the inflammatory system.²⁵

Physiologically, the pharynx is a very easily narrowed area in its overall expansion.²⁶ The activity of widening pharyngeal muscles, especially the genioglossus and palatini tensor muscles that oppose the pharyngeal tendency to collapse as a protective mechanism.²⁷ Changes in the mechanism are associated with obstructive sleep apnea disorder syndrome. Treatment options for OSA include weight loss, position therapy, oral appliances, positive continuous airway pressure (CPAP), and surgery. Operations offer a viable alternative to nasal CPAP in patients who are intolerant of nasal CPAP. In that case, oral appliances such as myofunctional therapy applied to OSA²⁸ has the aim of strengthening the nasopharyngeal and oropharyngeal muscles which contribute to reducing airway collapse during sleep. the exact mechanism by which Oral

Myofunctional Therapy helps with Sleep Respiratory Disorders is still unclear to this day.³⁰

At this stage, a systematic review is needed to prove the level of scientific evidence Oral myofunctional therapy as a future treatment for Obstructive Sleep Apnea in children. The aim of this study is to systematically review the literature for articles evaluating Oral Myofunctional Therapy exercises as a treatment for OSA in children.

METHODS

Search Strategy

A search was performed on Web of Science, Scopus, and The Cochrane Library. Studies published from 2010 to 2020 that the treatment with isolated Oral Myofunctional Therapy in subjects with OSA were included. MeSH terms and keywords used for the search included various combinations of the following: "myofascial reeducation," "myofunctional therapy," "obstructive sleep apnea," "orofacial myotherapy,"

"oral myotherapy," "sleep," and "sleep apneasyndromes. One example of search is: ("Myofunctional Therapy" AND "Sleep Apnea Syndromes") OR ("sleep" AND ("myofascial reeducation" OR "myofunctional therapy" OR "rapid maxillary expansion")) or each of the searches, the titles and abstracts were rescreened and the full text versions of articles that met criteria were downloaded. Full texts were reviewed and any referenced articles that were not already obtained were ordered and obtained. "Related citations" were also reviewed during these searches, and the "cited by" function on Google Scholar was also used to identify any additional studies

The flowchart in Figure 2 identifies the included and excluded articles at each stage. Sixty were assessed, including 60 articles from the electronic databases, 0 from the manual hand search. 50 records screened, 30 records excluded, 22 full-text articles assessed for eligibility and 10 full text articles included




Figure 2: A flow chart describing the search methodology and numbers of articles included/excluded at each stage

LITERATURE REVIEW

In this systematic review there are study selection: inclusion criteria for this review were: 1) children (<18 years old) with OSA, 2) all languages, 3) all study designs and publication

types were considered, 4) Article 2011-2020 year, and 5) both published and unpublished data were sought out. Exclusion criteria were: 1) studies that are not about RME as treatment for OSA, and 2) adult.

Table 3: Study design and treatment protocol

Author (year)	Study Type	N	f/m (mean age)	Variables analyzed	Treatment	Conclusion
Caprioglio et al., (2014) ³¹	Quasi-experimental, not randomized, no control	14	(7.1 ± 0.6)	AHI SpO2	Rapid maxillary expansion (6months)	Treatment improve SAHS (Sleep Apnea-Hypopnea Syndrome)
Rabasco et al., (2014) ³²	Quasi-experimental	40	(4-8)	AHI	Rapid maxillary expansion (6 months)	Data confirm the efficacy of Orthodontic treatment for children with slight or moderate SAHS
Villa et al., (2014) ³³	Quasi-experimental control group, not randomized	52	15/37 (5.03)	AHI SpO2	Rapid maxillary expansion (6 months)	Treatments improve SAHS.
Fastuca et al., (2015) ³⁴	Quasi-experimental no control group, not randomized	15	11/4 (7.5 ± 0.3)	AHI SpO2	Rapid maxillary expansion	RME improves oxygen saturation for patients with posterior crossbite
Villa et al., (2015) ³⁵	Quasi-experimental no control group, not randomized	40	17/23 (6.3 ± 1.6)	AHI SpO2	Rapid maxillary expansion	It is important to start orthodontic treatment early to improve treatment efficiency
Pireleli et al., (2015) ³⁶	Clinical evaluation	31	(8,68 years old)	AHI SpO2	Rapid maxillary expansion (6 months)	RME treatment for pediatric OSA
Villa et al., (2017) ³⁷	Case control study	54	Sleep-disordered breathing (7.1 ± 2.5), Healthy children (7.8 ± 2.2)	AHI	<u>Myofunctional therapy (6 months)</u>	<u>Myofunctional therapy can be used to integrate medical and surgical treatments for OSA and help restore the resting posture of the tongue; appropriate oral, lingual and facial muscle patterns; nasal breathing; normal lip posture; and correct swallowing patterns</u>
Klauer (2018) ³⁸	Case study	1	9 years old	AHI	<u>Myofunctional therapy (3 months)</u>	<u>Myofunctional therapy is a great tool in our armamentarium for treating children and adults with malocclusion or OSA</u>
Hsu et al. (2018)	Clinical evaluation	54	4-16 years old	AHI	<u>Passive myofunctional therapy (3 months)</u>	<u>Passive myofunctional therapy is a valid alternative treatment for pediatric OSA</u>
Shim et al., (2019) ³⁹	Case reports	2	7 years old	AHI SpO2	<u>Passive myofunctional therapy (6months)</u>	<u>Sleep Disorder Breathing in early childhood can have adverse effects on myofunctional balance and is associated with malocclusion. Orthodontic treatment, alone does not guarantee that these issues will be resolved. Myofunctional therapy may facilitate successful orthodontic treatment and maintenance</u>

Table 4: Cephalometric measurements before and after treatment Myofunctional Tools in Children with Sleep Disorders: Two Case Reports³⁹

Case Reports	SNA (81)	SNB(77)	ANB (3)	APDI (81)	FMA (26)	U1 to SN (105)	IMPA (95)	Interincisal angle (122)	Incisal overjet (3,3)	Incisal overbite (2,3)	U-nasolabial angle	L-Nasolabial angle	Nasolabial angle (100)	
Shim et al (2019)														

³⁹										(20)	(80)	
Before treatment (1)	79,9	73,9	6	74,7	25,5	110,2	94,4	122,5	7,2	3,4	12,1	68,8
After treatment (1)	79,7	74,3	5,4	75,3	25,9	101	96,8	128,7	3,7	2,3	19,8	71,3
Before treatment (2)	71,9	70,6	1,4	73,3	39,3	99,4	85,1	131,1	3,8	-1,4	37,6	83,2
After treatment (2)	72	71,5	0,5	77,5	37	93,7	87,2	136,2	0,5	-1,2	36,1	81,8

Based on (Table 4) Caprioglio et al.³¹ reported not randomised quasi-experimental with no control of 14 children who received myofunctional therapy using rapid maxillary expansion. The exercise group was followed up for 6 months. The exercise is repeated several times a day in 6 months. Further in table 3 with other studies. In contrast to (Table 4) the case report shows cephalometric measurements before and after the treatment of myofunctional devices in children with respiratory disorders during sleep. The different with Klauer³⁸ study design case study with 1 children and the exercise using myofunctional device is only 3 months that can be a great tool in our armamentarium for treating children and adults with malocclusion or OSA.

Case report 1 (Table 4) On extraoral examination, lateral convex profile and lip disability were observed. The incisors of proklin (U1 to SN 110.2 °), substantial overjet (7.2 mm) and normal overbite (3.4 mm) were recorded in cephalometric analysis. Large ANB (6.0 °) and reduced APDI (74.7 °) were also recorded. FMA is 25.5 °, which means normal vertical growth. Furthermore, the tendency of the class II framework with the mandible being reexamined with respect to the maxilla, was observed. As for soft tissue analysis, the upper lip is protruding (Nasolabial angle 80.9°) and the lower lip is eluted again (L-nasolabial angle 68.8 °). In the analysis of the cast model, the molar relationship is the terminal flush plane and the canine relationship is class I. The upper and lower arches are narrow. Patients were diagnosed with class II division 1 as a consequence of Sleep Disorder Breathing.³⁹

After 6 months of treatment, U1 to SN decreased from 110.2 ° to 101.1° and IMPA increased from 94.4° to 96.8° (Table 4). Overjet was reduced from 7.2 mm to 3.7 mm, and overbite from 3.4 mm to 2.3 mm. The nasolabial angle and the L-nasolabial angle increased from 80.9° to 91.1° and 68.8° to 71.3°, respectively. AHI has decreased from 1.3 to 0.6, and the average SpO2 has increased from 96.6% to 97.2%. Oral breathing is returned to nasal breathing, and moderate lip competence with decreased bruxism is noted.³⁹ Case report 2 (Table 4) On extraoral examination, convex lateral profile, and poor lip competence were observed. On intraoral examination, the tongue offered with an anterior openbite was found. The cephalometric analysis showed retroclined upper incisors (U1 to SN 99.4°) and lower incisors (IMPA 85.1°). A reduced ANB (1.4°) and APDI (73.3°) were

also recorded. FMA is 39.3°, which means vertical growth patterns. The pattern of the malocclusion framework is ambiguous because ANB and APDI are conflicting. The nasolabial angle and the nasolabial angle are both reduced. In the cast model analysis, the molar relationship is the terminal flush plane and 3 deciduous canines (# 53, 73, 83) are lost prematurely. The diameter of the mandible is shifted about 2.6 mm to the right. Overbite -1.4 mm and overjet 3.8 mm. The upper and lower curved shapes are tapered and ovoid respectively. The patient was diagnosed with Angle 2 malnutrition class 2 division 2 and had symptoms of Sleep Disorder Breathing³⁹

After 6 months of treatment, there was an increase in APDI from 73.3° to 77.5°, which is within the normal range (Table 4). Clinically, convex lateral facial profile is also found to decrease. The bimolar width between the dento-gingival junction center of the first primary molar has increased from 21.4 mm to 22.9 mm in the maxilla, and from 22.0 mm to 23.3 mm in the lower jaw. In contrast, the bimolar width between the dento-gingival junction center of the first permanent molar has decreased from 29.5 mm to 28.3 mm in the maxilla, and from 31.3 mm to 31.1 mm in the mandible. AHI decreased from 1.8 to 1.0 after 6 months of treatment, and the mean SpO2 increased from 96.2% to 97.3%. Respiratory Sleep Disorders are improved with Myofunctional therapy.³⁹

DISCUSSION

Myofunctional therapy has the potential to be an option for the treatment of OSA.⁴⁰ This is defined as a treatment for facial and mouth muscles, which is very important for the maintenance of craniofacial integrity to achieve normal nasal breathing. Re-education of myofunctional therapy trains normal and strong sucking, good mastication using both sides of the jaw, normal swallowing, normal tongue position, and nasal breathing with lips in good contact at rest. Nasal breathing upon awakening and sleeping is a demonstration of normal respiratory function, and persistence of mouth breathing is an indicator of abnormal respiratory function.

Myofunctional therapy requires the involvement of at least one parent and child for a minimum of 10 minutes of active exercise both in the morning and at night. Maintaining this routine has proven challenging with young children and

compliance has been limited, especially if there is no routine contact with myofunctional specialists who can provide support to parents and children.⁴¹

Recently, myofunctional therapy (MFT) has been suggested as an additional treatment of Sleep Disorder Breathing (SDB) in children.⁴² Results of studies conducted in children with orthodontic problems have shown that extensive, well-controlled, isolated myofunctional therapy can lead to a return to normal orofacial anatomy. In adults, there is an increase in OSA and snoring as well.^{43,44,45} But usage of myofunctional therapy itself when dealing with pediatric SDB has not been widely investigated and the long-term effects of myofunctional therapy on SDB are still unknown. Problems where myofunctional therapy has been reported: (1) current form MFT is difficult for children under 4 years, (2) poor compliance with daily exercise and the absence of ongoing parental involvement with exercises for children are the main causes of treatment failure. Preliminary studies are indicated that the use of functional oral tools is thought of induces some extra muscle activity during sleep (also called "passive myofunctional therapy" [PMFT]) can reduce mouth breathing and have impact on the position of the mandible.

CONCLUSION

Therefore a systematic literature review shows that oral myofunctional therapy for future treatment of obstructive sleep apnea in children (OSA).

REFERENCES

1. Agarwal L, Gupta A. Role of Orthodontics in Obstructive Sleep Apnea- An Orthodontic Review. *J Orthod Endod*. 2016;1-5.
2. Patino et al., Obstructive sleep apnoea in children: perioperative considerations. *British Journal of Anaesthesia*. Oxford University Press. 2013;1-10.
3. Lee CH, Hsu WC, Chang WH, et al. Polysomnographic findings after adenotonsillectomy for obstructive sleep apnoea in obese and non-obese children: a systematic review and meta-analysis. *Clin Otolaryngol* 2016;41: 498-510.
4. Turnbull CD, Bratton DJ, Craig SE, et al. Inpatients with minimally symptomatic OSA can baseline characteristics and early patterns of CPAP usage predict those who are likely to be longer-term users of CPAP. *J Thorac Dis* 2016;8: 276-281.
5. Donovan LM, Boeder S, Malhotra A, et al. New developments in the use of positive airway pressure for obstructive sleep apnea. *J Thorac Dis* 2015; 7: 1323-1342.
6. Barbe F, Durán-Cantolla J, Sánchez-dela-Torre M, et al. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. *JAMA* 2012; 307: 2161-2168.
7. Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. *Circulation* 2010; 122: 352-360.
8. American Academy of Pediatrics. Clinical practice guideline on the diagnosis and management of childhood obstructive sleep apnea syndrome. *Pediatrics* 2012;130 (3):576-684.
9. Camacho M, Cortal V, Capasso R. Comprehensive review of surgeries for obstructive sleep apnea syndrome. *Braz J Otorhinolaryngol* 2013;79:780-8.
10. Katz ES, D'Ambrosio CM. Pediatric obstructive sleep apnea syndrome. *Clin Chest Med* 2010; 31: 221-34.
11. Brown K. A pragmatic approach to pediatric obstructive sleep apnea. In: Bissonnette B, ed. *Pediatric Anesthesia Basic Principles—State of the Art—Future*. Shelton, CT: PMPH-USA, 2011; 988-93.
12. Yuan H, Pinto SJ, Huang J, et al. Ventilatory responses to hypercapnia during wakefulness and sleep in obese adolescents with and without obstructive sleep apnea syndrome. *Sleep* 2012; 35:1257-67.
13. Lee SY, Guillemainault C, Chiu HY, Sullivan SS. Mouth breathing, "nasal disuse," and pediatric sleep-disordered breathing. *Sleep Breath*. 2015;19(4):1257-64.
14. Verma RK, Johnson-J JR, Goyal M, Banumathy N, Goswami U, Panda NK. Oropharyngeal exercises in the treatment of obstructive sleep apnoea: our experience. *Sleep Breath*. 2016;20(4):1193-201.
15. Camacho M, Cortal V, Abdullatif J, Zaghi S, Ruoff CM, Capasso R et al. Myofunctional therapy to treat obstructive sleep apnea: a systematic review and meta-analysis. *Sleep*. 2015;38(5):669-75.
16. Diaferia G, Badke L, Santos-Silva R, Bommarito S, Tufk S, Bittencourt L. Effect of speech therapy as adjunct treatment to continuous positive airway pressure on the quality of life of patients with obstructive sleep apnea. *Sleep Med*. 2013;14(7):628-35.
17. Marcus CL, Moore RH, Rosen CL, et al. A randomized trial of adenotonsillectomy for childhood sleep apnea. *N Engl J Med* 2013; 368: 2366-76.
18. Spruyt K, Gozal D. REM and NREM sleep-state distribution of respiratory events in habitually snoring school-aged community children. *Sleep Med* 2012; 13: 178-84.
19. Niesters M, Overdyk F, Smith T, Aarts L, Dahan A. Opioid-induced respiratory depression in paediatrics: a review of case reports. *Br J Anaesth* 2013; 110: 175-82.
20. Gulotta et al., Risk Factors for Obstructive Sleep Apnea Syndrome in Children: State of the Art. *International Journal Environmental Research and Public Health*. 2019; 1-20.
21. Burghard, M.; Bro'zek-M'adry, E.; Krzeski, A. Sleep disordered breathing in children—Diagnostic questionnaires, comparative analysis. *Int. J. Pediatr. Otorhinolaryngol.* 2019, 120, 108-111.
22. Kadmon, G.; Chung, S.A.; Shapiro, C.M. I'M SLEEPY: A short pediatric sleep apnea questionnaire. *Int. J. Pediatr. Otorhinolaryngol.* 2014, 78, 2116-2120.
23. Villa, M.P.; Paolino, M.C.; Castaldo, R.; Vanacore, N.; Rizzoli, A.; Miano, S.; Del Pozzo, M.; Montesano, M. Sleep Clinical Record: an aid to rapid and accurate

diagnosis of Paediatric Sleep Disordered Breathing. *Eur. Respir. J.* 2013; 41, 1355–1361.

24. Bhushan, B.; Khalyfa, A.; Spruyt, K.; Kheirandish-Gozal, L.; Capdevila, O.S.; Bhattacharjee, R.; Kim, J.; Keating, B.; Hakonarson, H.; Gozal, D. Fatty-acid binding protein 4 gene polymorphisms and plasma levels in children with obstructive sleep apnea. *Sleep Med.* 2011; 12, 666–671.

25. Kim, J.; Bhattacharjee, R.; Snow, A.B.; Capdevila, O.S.; Kheirandish-Gozal, L.; Gozal, D. Myeloid-related protein 8/14 levels in children with obstructive sleep apnea. *Eur. Respir. J.* 2010; 35, 843–850.

26. Nisbet, L.C.; Yiallourou, S.R.; Walter, L.M.; Horne, R.S. Blood pressure regulation, autonomic control and sleep disordered breathing in children. *Sleep Med. Rev.* 2014; 18, 179–189.

27. Magliulo, G.; Iannella, G.; Polimeni, A.; De Vincentis, M.; Meccariello, G.; Gulotta, G.; Pasquariello, B.; Montevercchi, F.; De Vito, A.; D'Agostino, G.; et al. Laryngopharyngeal reflux in obstructive sleep apnoea patients: Literature review and meta-analysis. *Am. J. Otolaryngol.* 2018; 39, 776–780.

28. Kheirandish-Gozal, L.; Gileles-Hillel, A.; Alonso-Alvarez, M.L.; Peris, E.; Bhattacharjee, R.; Terán-Santos, J.; Duran-Cantolla, J.; Gozal, D. Effects of adenotonsillectomy on plasma inflammatory biomarkers in obese children with obstructive sleep apnea: A community-based study. *Int. J. Obes.* 2015; 39, 1094–1100.

29. Villa, M.P.; Supino, M.C.; Fedeli, S.; Rabasco, J.; Vitelli, O.; Del Pozzo, M.; Gentile, G.; Lionetto, L.; Barreto, M.; Simmaco, M. Urinary concentration of 8-isoprostane as marker of severity of pediatric OSAS. *Sleep Breath* 2014; 18, 723–729.

30. De Luca Canto, G.; Pacheco-Pereira, C.; Aydinoz, S.; Major, P.W.; Flores-Mir, C.; Gozal, D. Diagnostic capability of biological markers in assessment of obstructive sleep apnea: A systematic review and meta-analysis. *J. Clin. Sleep Med.* 2015; 11, 27–36

31. Caprioglio A, Meneghel M, Fastuca R, Zecca PA, Nucera R, Nosetti L. Rapid maxillary expansion in growing patients: correspondence between 3-dimensional airway changes and polysomnography. *Int J Pediatr Otorhinolaryngol.* 2014;78:23-7

32. Rabasco et al. Rapid maxillary expansion outcomes in treatment of obstructive sleep apnea in children. *Sleep Medicine.* Volume 16 Issue 6 June 2014: 709-716

33. Villa MP, Castaldo R, Miano S, Paolino MC, Vitelli O, Tabarrini A. Adenotonsillectomy and orthodontic therapy in pediatric obstructive sleep apnea. *Sleep Breath.* 2014;18:533-9.

34. Fastuca R, Perinetti G, Zecca PA, Nucera R, Caprioglio A. Airway compartments volume and oxygen saturation changes after rapid maxillary expansion: longitudinal correlation study. *Angle Orthod.* 2015;85:955-61

35. Villa MP, Rizzoli A, Rabasco J, Vitelli O, Pietropaoli N, Cecili M, et al. Rapid maxillary expansion outcomes in treatment of obstructive sleep apnea in children. *Sleep Med.* 2015;16:709-16

36. Pirelli P, Saponara M, Guilleminault C. Rapid Maxillary Expansion in Children with Obstructive Sleep Apnea Syndrome. *2015;27:761-6*

37. Villa et al. Can myofunctional therapy increase tongue tone and reduce symptoms in children with sleep-disordered breathing? *Sleep Breath* (2017) 21:1025–1032

38. Klauer D. Myofunctional therapy plays a key role in the orthodontic practice. *Orthodontic practice.* 2018. Volume 9 Number 4: 22-30

39. Shim et al. Effects of Myofunctional Appliance in Children with Sleep-Disordered Breathing: Two Case Reports. *J Korean Acad Pediatr Dent.* 2019; 119-124

40. Kayamori F. Effects of orofacial myofunctional therapy on the symptoms and physiological parameters of sleep breathing disorders in adults: a systematic review. *Rev. CEFAC.* 2017 Nov-Dec; 19(6):868-878

41. Felicio et al. Orofacial motor functions in pediatric obstructive sleep apnea and implications for myofunctional therapy. *International Journal of Pediatric Otorhinolaryngology.* 2016;5-11

42. Guilleminault C, Huang YS. From oral facial dysfunction to dysmorphism and the onset of pediatric OSA. *Sleep Med Rev* 2018;40:203–14.

43. Guimaraes KC, Drager LF, Genta PR, et al. Effects of oropharyngeal exercises on patients with moderate obstructive sleep apnea syndrome. *Am J Respir Crit Care Med* 2009;179:962–6.

44. Guilleminault C, Akhtar F. Pediatrics sleep-disordered breathing: new evidences on its development. *Sleep Med Rev* 2015;14:1–11.

45. Villa MP, Evangelisti M, Martella S, et al. Can myofunctional therapy increase tongue tone and reduce symptoms in children with sleep-disordered breathing? *Sleep Breath* 2017;21(4): 1025–32.